Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin in previously treated c-Met-positive non-small cell lung cancer
2023-507902-15-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, open-label, single-arm trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc. Primary endpoint: Overall Response Rate. Planned start Mar 2019; status: authorised.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-507902-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507902-15-00.